Luspatercept
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Thalassemia
Conditions
Thalassemia
Trial Timeline
Feb 5, 2018 → Nov 28, 2022
NCT ID
NCT03342404About Luspatercept
Luspatercept is a phase 2 stage product being developed by Merck for Thalassemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03342404. Target conditions include Thalassemia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03342404 | Phase 2 | Completed |
| NCT02604433 | Phase 3 | Completed |
| NCT02631070 | Phase 3 | Completed |
| NCT02268409 | Phase 2 | Completed |
| NCT02268383 | Phase 2 | Completed |
| NCT01749540 | Phase 2 | Completed |
| NCT01749514 | Phase 2 | Completed |
Competing Products
20 competing products in Thalassemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| luspatercept | Merck | Phase 2 | 52 |
| ACE-536 | Merck | Phase 2 | 52 |
| luspatercept | Merck | Phase 2 | 52 |
| Deferasirox | Novartis | Approved | 85 |
| Blood sample | Novartis | Pre-clinical | 23 |
| deferasirox + placebo | Novartis | Phase 2 | 52 |
| Zoledronic acid + Placebo | Novartis | Phase 2/3 | 65 |
| deferasirox | Novartis | Approved | 85 |
| deferasirox | Novartis | Phase 3 | 77 |
| ICL670 + deferoxamine | Novartis | Phase 3 | 77 |
| ruxolitinib | Novartis | Phase 2 | 52 |
| Deferasirox | Novartis | Phase 2 | 52 |
| Deferasirox dispersable tablet (DT) + Deferasirox film coated tablet (FCT) | Novartis | Phase 2 | 52 |
| Zoledronic Acid | Novartis | Approved | 85 |
| Deferasirox | Novartis | Phase 2 | 52 |
| Deferasirox | Novartis | Approved | 85 |
| Deferasirox + Deferoxamine (DFO) | Novartis | Phase 2 | 52 |
| Deferasirox | Novartis | Phase 1 | 33 |
| Deferasirox | Novartis | Phase 3 | 77 |
| Deferasirox | Novartis | Phase 2 | 52 |